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Abstract
Purpose—To assess the prevalence of postdischarge nausea and vomiting (PDNV) after Le Fort 
I osteotomy with and without the use of a multimodal antiemetic protocol shown to decrease 
postoperative nausea and vomiting (PONV).
Materials and Methods—Consecutive patients undergoing Le Fort I osteotomy with or without 
additional procedures at a single academic institution formed the intervention cohort for an 
institutional review board–approved prospective clinical trial with a retrospective comparison 
group. The intervention cohort was managed with a multimodal antiemetic protocol. The 
comparison group consisted of consecutive patients who underwent similar surgical procedures at 
the same institution before protocol implementation. All patients were asked to complete a 
postdischarge diary documenting the occurrence of nausea and vomiting. Those who completed 
the diaries were included in this analysis. Data were analyzed with the Fisher exact test and the 
Wilcoxon rank sum test. A P value less than .05 was considered significant.
Results—Diaries were completed by 85% of patients in the intervention group (79 of 93) and 
75% of patients in the comparison group (103 of 137). Patients in the intervention (n = 79) and 
comparison (n = 103) groups were similar in the proportion of patients with validated risk factors 
for PDNV, including female gender, history of PONV, age younger than 50 years, opioid use in 
the postanesthesia care unit (PACU), and nausea in the PACU (P = .37). The prevalence of PDNV 
was unaffected by the antiemetic protocol. After discharge, nausea was reported by 72% of 
patients in the intervention group and 60% of patients in the comparison group (P = .13) and 
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vomiting was reported by 22% of patients in the intervention group and 29% of patients in the 
comparison group (P = .40).
Conclusion—Modalities that successfully address PONV after Le Fort I osteotomy might fail to 
affect PDNV, which is prevalent in this population. Future investigation will focus on methods to 
minimize PDNV.
Postoperative nausea and vomiting (PONV) has been studied extensively. Guidelines have 
been developed to help minimize PONV, and implementation of a multi-modal protocol has 
recently been shown to effectively decrease PONV in the orthognathic surgical 
population.1-3 Postdischarge nausea and vomiting (PDNV), although also common, is less 
well understood.4 The recently updated Society for Ambulatory Anesthesia guidelines for 
the management of PONV emphasize that “PDNV is still a significant problem” despite 
advances in the prevention of PONV.3 In 1 systematic review, 17% of patients (range, 0 to 
55%) developed postdischarge nausea (PDN) and 8% (range, 0 to 16%) developed 
postdischarge vomiting (PDV)5; another systematic review reported that 32.6% developed 
PDN and 14.7% developed PDV.6 PDNV can have a considerable impact on patients, their 
at-home providers, and the health care system. PDNV can delay resumption of daily 
activities and can result in readmission.7-9 Nausea and vomiting after surgery also can lead 
to wound complications and stress on home care providers. Intermaxillary elastic traction, 
hypoesthesia, and facial edema make PDNV particularly distressing after orthognathic 
surgical procedures.
Despite the negative effect PDNV can exert on recovery, few patients who develop PDNV 
contact their providers; thus, providers are likely to underestimate this problem.7 However, 
patients place great emphasis on this complication. Patient dissatisfaction has been 
statistically linked with PONV,10,11 and evidence shows that fear of PONV eclipses even 
fear of pain.12
Validated risk factors for PDNV have been derived from a prospective multicenter cohort 
study that assessed nausea and vomiting for 48 hours postoperatively in more than 2,000 
patients. These risk factors include female gender, age younger 50 years, history of PONV, 
opioid administration in the postanesthesia care unit (PACU), and nausea in the PACU. The 
use of ondansetron intraoperatively, smoking status, and types of surgery were not statistical 
predictors of PDNV.3,13
PONV has been shown to occur frequently after orthognathic surgery.14,15 A multimodal 
protocol that decreased prevalence of PONV after Le Fort I osteotomy with or without 
additional procedures has recently been reported.1 The preponderance of studies evaluating 
modalities to address PONV simply have evaluated effectiveness at discharge from the 
recovery room or at 24 hours postoperatively; thus, this study also was designed to evaluate 
PDNV. The purposes of this study were to assess the prevalence of PDNV after Le Fort I 
osteotomy, with or without additional procedures, and to evaluate the impact of the 
multimodal protocol on PDNV. The authors hypothesized that the prevalence of PDNV after 
Le Fort I osteotomy would be high and that it would be decreased by protocol 
implementation.
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A prospective, institutional review board–approved clinical trial (919.966.3113, University 
of North Carolina, Chapel Hill) with a retrospective comparison group was registered with 
ClinicalTrials.gov. (NCT01592708) This study showed a statistical decrease in 
postoperative nausea (PON) and postoperative vomiting (POV) experienced by patients 
undergoing Le Fort I osteotomy, with or without additional procedures, after the 
introduction of a multimodal antiemetic protocol. PDNV was studied in the same patients 
under the same institutional review board approval to assess the prevalence of PDNV before 
and after protocol implementation and to test the hypothesis that the protocol also would 
decrease PDNV. Guidelines of the Declaration of Helsinki were followed. The authors state 
that the report includes every item in the Strengthening the Reporting of Observational 
Studies in Epidemiology checklist for cohort observational clinical studies.
Consecutive patients at least 15 years old undergoing Le Fort I osteotomy, with or without 
additional procedures, from July 2012 through February 2014 were recruited as the 
intervention cohort receiving a multi-modal antiemetic protocol that is presented in Table 
1.1,16-29 The protocol was based largely on consensus guidelines.2 A detailed rationale for 
protocol development and a description of inclusion and exclusion criteria have been 
reported.1
The comparison group was comprised of a subset of consecutively enrolled patients with 
American Society of Anesthesiologists physical status I and II who underwent orthognathic 
surgery at the same institution from June 2008 through June 2012, before implementation of 
the multimodal antiemetic protocol. In patients in the comparison group, all anesthetics were 
at the discretion of the anesthesia care team; the breakdown of anesthetics and analgesics 
administered is presented in Table 2. The sole inclusion criterion added for the PDNV 
cohort was diary completion.
A post-orthognathic surgical daily health diary included specific items relating to nausea and 
vomiting.30,31 The comparison cohort completed a 90-day diary, the first 7 days of which 
were assessed for this study. The prospective cohort completed a 7-day diary. Beginning on 
postoperative day 1, patients were asked daily whether they experienced nausea or vomiting. 
They also were asked to rank their experience of nausea on a 5-point scale, from no trouble 
or concern (1) to lots of trouble or concern (5). PDN was considered resolved when the 
patient reported little to no trouble or concern related to nausea. PDV was considered 
resolved when patients reported no vomiting. Days to resolution of PDN and PDV were 
determined by the postoperative day on which resolution was reported; thus, 1 day to 
resolution meant that patients reported little to no trouble or concern related to nausea or no 
vomiting on postoperative day 1 and thus experienced no PDN or PDV.
Trained research associates described the project to each patient and obtained written 
consent or assent with parental permission and Health Insurance Portability and 
Accountability Act authorization to review clinical records. The same research associates 
provided the diaries to patients before discharge from the hospital.
Brookes et al. Page 3













Patients returned for routine postoperative visits and were asked to return diaries once 
completed. If a patient did not return the diary, a research associate provided the patient with 
a preaddressed envelope to facilitate diary return by mail. Diaries were electronically 
scanned for data retrieval.
Established patient-related risk factors for PONV, including female gender, nonsmoking 
status, and history of PONV or motion sickness, were collected from medical records.32 
Further, validated risk factors for PDNV (female gender, history of PONV, age <50 yr, 
opioid use in the PACU, and nausea in the PACU) were recorded.13 Medical records were 
reviewed by 2 independent individuals; any differences were resolved by joint record 
review.
The primary predictor variable was protocol implementation. The primary outcome 
variables were PDN and PDV. Bivariate comparisons between the intervention and control 
groups were performed using the Fisher exact test for nominal variables and the exact 
Wilcoxon rank sum test for continuous variables using SAS 9.1 (SAS Institute, Cary, NC). 
A P value less than .05 was considered statistically significant.
Results
Diaries were completed by 85% of patients in the intervention group (n = 79) and 75% of 
patients in the comparison group (n = 103). The total intervention (n = 93) and comparison 
(n = 137) groups were similar in gender (P = .29), race (P = .85), age (P = .75), proportion 
of patients with known risk factors for PONV (including female gender, nonsmoking status, 
history of PONV or motion sickness, and history of migraine headaches; P = .34), 
percentage undergoing bimaxillary surgery (60% in each group), and percentage for whom 
surgical time was longer than 180 minutes (P = .51). The only statistically significant 
difference between those who completed diaries and those who did not according to these 
traits was that there were fewer female patients who did not complete diaries in the 
comparison cohort (47 vs 71%; P = .011; Table 3). Despite this difference, those who 
completed diaries in the intervention and comparison groups were similar in known risk 
factors for PONV (Fig 1).
The patients in each group who completed diaries also were compared for validated risk 
factors for PDNV. Fifty-eight percent of patients in the intervention group and 71% of 
patients in the comparison group were female (P = .08). No patients were older than 50 
years. History of PONV was noted for 8% of patients in the intervention group and for 10% 
of patients in the comparison group (P = .62). Opioids were administered in the PACU to 
more patients in the intervention group (70%) than to patients in the comparison group 
(35%; P < .0001). However, fewer patients in the intervention group (5%) experienced 
nausea in the PACU than did patients in the comparison group (20%; P = .003). 
Nonetheless, the proportion of patients with a given number of validated risk factors was 
similar in each group (P = .37; Fig 2).
PON was significantly decreased by the antiemetic protocol in the intervention versus 
comparison cohort (23 vs 71%; P < .01). Likewise, POV was significantly decreased in the 
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intervention versus comparison cohort (10 vs 30%; P < .01). The difference between cohorts 
was similar to that observed in the previous PONV report comparing 93 and 137 patients.1
Diary analysis for PDNV showed that 72% of patients who received the antiemetic protocol 
versus 60% of patients in the comparison group reported PDN (P = .09) and that 22% of 
patients in the intervention group versus 29% of patients in the comparison group reported 
PDV (P = .24; Fig 3).
Median day on which nausea resolved was day 4 (interquartile range [IQR], days 1 to 7) for 
the intervention group and day 2 (IQR, days 1 to 7) for the comparison group. Median day 
on which patients reported no vomiting was day 1 (IQR, day 1) for the intervention group 
and day 1 (IQR, days 1 to 2) for the comparison group. There was no statistically significant 
difference in time to resolution of PON (P = .24) or POV (P = .22) between the 2 groups.
Discussion
The authors hypothesized that the prevalence of PDNV would be high after Le Fort I 
surgery and that the prevalence would be decreased by the antiemetic protocol. The 
prevalence of PDNV was indeed very high in this patient population. However, although 
this multimodal antiemetic protocol statistically decreased PON and POV,1 it had no 
statistical impact on PDNV. There was a trend toward slightly more PDN that lasted slightly 
longer in the intervention group, but a trend toward more PDV in the comparison group. 
Sample size limits the ability to detect relevance, but these findings support the concept that 
PONV and PDNV are different entities that must be addressed separately.3,7,13
PDN lasted longer in the present series (intervention group: mean, 4.2 days; standard 
deviation [SD], 2.83 days; comparison group: mean, 3.74 days; SD, 2.96 days) than in 
another large series (mean, 1.7 days; SD, 1.3 days).13
When attempting to address PDNV, risk factor assessment is crucial so high-risk patients 
can be identified and managed appropriately. According to the simplified risk score for 
PDNV by Apfel et al,13 PDNV will be experienced by approximately 10, 20, 30, 50, 60, and 
80% of patients with 0, 1, 2, 3, 4, or 5 of the following risk factors: female gender, age 
younger than 50 years, history of PONV, opioid administration in the PACU, and nausea in 
the PACU. Sensitivity and specificity of the risk score are 65 to 70%.3 Most patients in each 
group in this series had no more than 2 risk factors. Prevalence of PDNV was higher than 
expected based on the simplified risk score, underscoring that much remains unknown about 
PDNV.
Although the role of surgery type remains controversial in PONV,3 the results of this study 
suggest that Le Fort I osteotomy could be an unrecognized high-risk surgery type for PDNV 
as an independent risk factor or as a result of confounding factors. The important dietary 
alterations required after orthognathic surgery, including Le Fort I osteotomy, could 
contribute to the prolonged duration of PDNV in this population. Unfortunately, the present 
sample is underpowered to identify risk factors for PDNV; however, additional investigation 
into risk factors for PDNV is important because better understanding of these risk factors 
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will enhance providers' ability to decrease this unpleasant postoperative problem shown to 
delay resumption of normal daily activities in the postoperative period.7
The protocol was initially designed to target PONV; however, several strategies 
implemented in the intervention cohort also have been linked to decreasing PDNV. A 
systematic review found that less PDNV is seen after total intravenous anesthetic (TIVA) 
than after use of volatile agents33; recent consensus guidelines highlight this.3 In contrast, 
White et al34 reported more PDNV in patients managed with TIVA than in those managed 
with a volatile agent. However, only those managed with a volatile agent received 
dolasetron; no other antiemetic strategies were used in this group of high-risk patients. 
Another systematic review found that dexamethasone statistically decreases PDN (relative 
risk [RR], 0.55), but not PDV.6 Methylprednisolone, the steroid administered to patients in 
the 2 groups in this study, has been shown to decrease late PONV extending to 24 hours and 
beyond.35,36
Ondansetron 4 mg has been shown to statistically decrease PDN (RR, 0.77) and PDV (RR, 
0.63).6 Combination therapy has been shown to decrease PDNV more than single agents.6,37 
Opioid-sparing analgesia is another strategy posited to decrease PDNV.38 Scopolamine has 
been shown to have equivalent effect to ondansetron and droperidol on nausea and vomiting 
in the 72 hours after surgery39 and to decrease nausea and vomiting further at 24 and 48 
hours after surgery when given in addition to ondansetron.40
Despite administration of a TIVA with combination antiemetic therapy that included 
steroids, scopolamine, ondansetron and opioid-sparing analgesia, there was no impact on 
PDNV in the intervention group.
Many medications currently used to prevent PONV have a relatively short half-life, which 
can limit their utility in the prevention of PDNV. One potential solution to this issue is 
administration of scheduled oral ondansetron postoperatively; this intervention, alone or in 
conjunction with administration of dexamethasone, has been shown to decrease PDNV, 
increase patient satisfaction, and improve quality of functional living.41,42 Other 
investigators have turned toward newer agents with longer half-lives. Among these are 
palonosetron, a serotonin (5-HT3) receptor antagonist with a 40-hour half-life and unique 
allosteric inhibition of 5-HT3 receptors in addition to positive cooperative binding.43 
Palonosetron shows promise in the management of nausea and vomiting in the first 72 hours 
after surgery3,38,44-46 and has a good safety profile: although corrected QT(QTc) 
prolongation has been reported with palonosetron in conjunction with sevoflurane,47 it is 
much less apt to cause QTc prolongation than are the other 5-HT3 receptor 
antagonists.44,46,48
Aprepitant and other neurokinin-1 receptor antagonists (NK1-RAs) also might play a role in 
the management of PDNV. NK1-RAs are competitive inhibitors of the receptors for 
substance P, which is linked to emesis; these agents show particular promise in the decrease 
of vomiting. NK1-RAs are nonsedating and do not cause QTc prolongation, although 
aprepitant does inhibit CYP3A4 in a dose-dependent fashion.3,38,45,49-51 A recent trial 
reported no difference in PDNV from 24 to 48 hours postoperatively in patients receiving 
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aprepitant versus placebo52; although it could be an important adjunct in the prevention of 
PDNV, further investigation into aprepitant's impact in the postdischarge period is indicated.
Acupoint stimulation of “pericardium 6,” located on the wrist, is low risk and might 
decrease PONV and PDNV; acupressure and other noninvasive acupoint stimulation 
techniques seem to be as effective as invasive acupoint stimulation.3,45,53
Limitations of this study include the small sample and use of a retrospective comparison 
group. As a result of the retrospective comparison group and slightly different exclusion 
criteria, confounding variables could have been introduced. The retrospective comparison 
group offered the advantage of comparison with existing treatment at the discretion of the 
anesthesia care team rather than with a prescribed alternative to the multimodal protocol. 
Practitioners should use caution in generalizing these findings to other populations.
This study found a high incidence of PDNV in patients undergoing Le Fort I osteotomy, 
with or without additional procedures, despite implementation of an antiemetic protocol that 
effectively decreased PONV in the same patients. Because PDNV is important for patient 
safety, productivity, and satisfaction, additional investigation into methods to minimize this 
postoperative complication in the orthognathic surgical population is indicated, particularly 
because more of these procedures are performed on an outpatient basis.
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Classic risk factors for PONV (including female gender, nonsmoking status, history of 
PONV or motion sickness, and history of migraine headaches) in diary responders in 
comparison versus intervention cohort. A, Comparison of number of patients with each risk 
factor. B, Comparison of number of patients with a given number of risk factors. Hx, 
history; PONV, postoperative nausea and vomiting
Brookes et al. Page 11














Validated risk factors for PDNV (including female gender, history of PONV, age <50 yr, 
opioid use in the PACU, and nausea in the PACU) for diary responders in comparison 
versus intervention cohort. A, Comparison of number of patients with each risk factor. B, 
Comparison of number of patients with a given number of risk factors. PACU, 
postanesthesia care unit; PDNV, postdischarge nausea and vomiting
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Comparison of prevalence of PONV and PDNV in diary responders in the comparison and 
intervention groups. PDNV, postdischarge nausea and vomiting; PONV, postoperative 
nausea and vomiting.
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Table 1
Summary of Multimodal Protocol Used for Patients in the Intervention Group1
1. Preoperative
 a. Scopolamine patch16
 b. Erythromycin 250 mg PO17-20
 c. Midazolam 1-2 mg IV per anesthesia care team
2. Fluids: crystalloid will be administered during the case—minimum 10 mL/kg
3. Induction, maintenance, antiemetics
 a. Propofol, remifentanil total IV anesthetic1,21,22
  i. Esmolol first line to achieve target SBP <90 mmHg at key parts of procedure
  ii. Additional antihypertensive agents as needed
   1. Avoid excessive opioids
   2. Avoid volatile agents as above
 b. Neostigmine: avoid if possible (paralysis not surgically necessary); if used, limit to maximum 2.5 mg unless patient safety dictates 
otherwise1,23
 c. Steroids per surgeon preference; typically Solu-Medrol 125 mg IV at beginning of case
 d. Droperidol 0.625 mg IV near end of case1,21
 e. Ondansetron 4 mg IV near end of case1,21
 f. Surgeons to evacuate gastric contents with a nasogastric tube at end of case
4. Analgesia in OR
 a. Ketorolac 30 mg IV at end of case1
 b. No morphine; fentanyl preferred, hydromorphone if necessary
5. PACU or floor
 a. Rescue medications for nausea or emesis1,24
  i. Promethazine 6.25-25 mg IV, PO, or PR
  ii. Dexamethasone 4 mg IV (PACU only)
  iii. Diphenhydramine 25-50 mg IV or PO
  iv. Ondansetron 4 mg IV or 4-8 mg ODT (if ≥6 h after first dose)
 b. Fluids: continue crystalloid in PACU until goal of ≥25 mL/kg is reached1,25
 c. Analgesia14,26-29
  i. No morphine; fentanyl preferred, hydromorphone if necessary
  ii. No codeine; hydrocodone or acetaminophen preferred; oxycodone if necessary
  iii. Ketorolac 30 mg IV q6h until conversion to PO analgesics, then scheduled ibuprofen 600 mg q6h1
 d. Prokinetics: repeat erythromycin 250 mg PO 8 hours after first dose in OR
 e. Steroids: redosed per surgeon preference
Abbreviations: IV, intravenous; ODT, orally disintegrating tablet; OR, operating room; PACU, postanesthesia care unit; PO, per oral; PR, per 
rectum; q6h, every 6 hours; SBP, systolic blood pressure.
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Table 2
Anesthetics Used in Retrospective Group
1. Anesthetic agents
 a. Volatile agents, 98%
 b. Nitrous oxide, 54%
2. Fluids: per anesthetist preference
3. Analgesia
 a. Morphine, 69%
 b. Codeine, 61%
4. Antiemetic: ondansetron, 97%
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